美国医疗保险计划中阿杜卡奴单抗的预估年度支出。
Estimated Annual Spending on Aducanumab in the US Medicare Program.
机构信息
Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.
RAND Corporation, Santa Monica, California.
出版信息
JAMA Health Forum. 2022 Jan 14;3(1):e214495. doi: 10.1001/jamahealthforum.2021.4495. eCollection 2022 Jan.
Abstract
This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.
摘要
本横断面研究考察了为符合批准的轻度认知障碍或轻度痴呆适应证的受益人群使用 aducanumab 而产生的医保上限和下限年度费用。
Zotero 插件